LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.2 -3.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.19

Max

1.24

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Aktsiakasum	-0.43
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+141.94% upside

Turustatistika
By TradingEconomics
Turukapital	-26M 76M
Eelmine avamishind	4.43
Eelmine sulgemishind	1.2

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. dets 2025, 15:21 UTC

Tulu

Correction to Home Depot Outlook Headline on Dec. 9

23. dets 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23. dets 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 21:21 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Hold Deposit in Escrow

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23. dets 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23. dets 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23. dets 2025, 19:13 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23. dets 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23. dets 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. dets 2025, 17:09 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23. dets 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23. dets 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23. dets 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank: Closing Expected Around Mid-January

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23. dets 2025, 16:02 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23. dets 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Receives Green Light for Acquisition in Poland

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica Doesn't Set Out Financial Details of Divestment

23. dets 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Deal Will Allow Focus on Core Markets

23. dets 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23. dets 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

141.94% tõus

12 kuu keskmine prognoos

Keskmine 3 USD 141.94%

Kõrge 4 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.